Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value


Radiomic profiles in diffuse glioma reveal distinct subtypes with prognostic value


Peng Lin, Yu-ting Peng, Rui-zhi Gao, Yan Wei, Xiao-Jiao Li, Su-Ning Huang, Ye-Ying Fang, Zhu-Xin Wei, Zhi-Guang Huang, Hong Yang & Gang Chen 



To evaluate a radiomic approach for the stratification of diffuse gliomas with distinct prognosis and provide additional resolution of their clinicopathological and molecular characteristics.


For this retrospective study, a total of 704 radiomic features were extracted from the multi-channel MRI data of 166 diffuse gliomas. Survival-associated radiomic features were identified and submitted to distinguish glioma subtypes using consensus clustering. Multi-layered molecular data were used to observe the different clinical and molecular characteristics between radiomic subtypes. The relative profiles of an array of immune cell infiltrations were measured gene set variation analysis approach to explore differences in tumor immune microenvironment.


A total of 6 categories, including 318 radiomic features were significantly correlated with the overall survival of glioma patients. Two subgroups with distinct prognosis were separated by consensus clustering of radiomic features that significantly associated with survival. Histological stage and molecular factors, including IDH status and MGMT promoter methylation status were significant differences between the two subtypes. Furthermore, gene functional enrichment analysis and immune infiltration pattern analysis also hinted that the inferior prognosis subtype may more response to immunotherapy.


A radiomic model derived from multi-parameter MRI of the gliomas was successful in the risk stratification of diffuse glioma patients. These data suggested that radiomics provided an alternative approach for survival estimation and may improve clinical decision-making.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00432-020-03153-6